Exposure to Polio Vaccine Through Aerial Vaccines and Nano Delivery Systems
Hildegarde Staninger, Ph.D.,
Â© Sept. 9, 2009 Presented at the NREP 2009 Virtual Conference, Des Plaines, IL
Oct. 5 & 6, 2009
The use of adenoviral protein envelopes as specific immunization and nano gene delivery systems has been observed in an individual, who was never vaccinated for polio or had parents who were vaccinated. A 1:128 Tier I, II, and III titer was observed through clinical testing of a female after exposure to aerial spraying for West Nile Virus in Anaheim, CA, during the spring of 2009. Use of PCR analysis showed positive protein band readings for KD-45 (Simian Green Monkey polio virus-40) as associated in the original cancer research findings of former leading American Cancer Institute’s researcher, Dr. Mary Sherman in the 1950’s. Amendments to the Chemical and Biological Warfare Act of 1949 in December 2007, state that under terrorist and riot control measures mass aerial immunizations may occur. Many of the new biological pesticides are made from various bio-nanotechnology materials that utilize the same technologies used in nasal vaccine technology.
HISTORICAL PROSPECTIVE OF AERIAL SPRAYING
The use of aerial manned and unmanned vehicles for the aerial spraying under State and Federal mandates for vector control began under the Geneva Act for Chemical and Biological Weapons in 1949. Over the years since its inception many amendments to this act and US parallel acts such as the Patriot Act of 2001, Space Preservation Act of 2001 and Weather Modification Research and Technology Act of 2005 1, 2, 3, 4 have included the following implementations under terrorist and riot control for aerial spraying of the mass population in selective city locations:
Weather Modification. Vector Control (insects, virus, and other similar vectors). Mass Inoculations of the Public.
The Defense Sciences Office of the Pathogen Countermeasures Program5, in September 23, 1998 funded the University of Michigan’s principal investigator, Dr. James Baker, Jr. Dr. Baker, Director of Michigan Nanotechnology Institute for Medicine and Biological Sciences under several DARPA grants. Dr. Baker developed and focused on preventing pathogens from entering the human body, which is a major goal in the development of counter measures to Biological Warfare. This research project sought to develop a composite material that will serve as a pathogen avoidance barrier and post-exposure therapeutic agent to be applied in a topical manner to the skin and mucous membranes. The composite is modeled after the immune system in that it involves redundant, non-specific and specific forms of pathogen defense and inactivation. This composite material is now utilized in many nasal vaccines and vector control through the use of hydro-gel, nanosilicon gels and actuator materials in vaccines.
Through Dr. Baker’s research at the University of Michigan; he developed dendritic polymers and their application to medical and biological science. He co-developed a new vector system for gene transfer using synthetic polymers. These studies have produced striking results and have the potential to change the basis of gene transfer therapy. Dendrimers are nanometer-sized water soluble polymers that can conjugate to peptides or carbohydrates to act as decoy molecules to inhibit the binding of toxins and viruses to cells. They can act also as complex and stabilize genetic material for prolonged periods of time, as in a “time released or delayed gene transfer”. Through Dr. Baker’s ground breaking research many pharmaceutical and biological pesticide manufacturers can use these principles in DNA vaccines specific applications that incorporate the Simian Monkey Virus SV40.
It is important to realize that under these acts and the current testing for pathogen countermeasures the general public may be exposed to these countermeasures without written permission for USDA Vector Control, Domestic Preparedness and Weapons of Mass Destruction counter measures.